| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 10052206 | The Journal of Urology | 2005 | 7 Pages |
Abstract
The overall benefit of monitoring serum PSA after treatment for prostate cancer remains controversial. Considering the potential dangers associated with incorrectly assuming the efficacy of new forms of treatment, the toxicity of administering salvage therapies of uncertain efficacy after BF has been identified and the anxiety associated with tracking posttreatment serum PSA, additional studies must be done to determine the appropriate use of this marker in properly treating patients after therapy.
Related Topics
Health Sciences
Medicine and Dentistry
Nephrology
Authors
FRANK A. VICINI, CARLOS VARGAS, ANTHONY ABNER, LARRY KESTIN, ERIC HORWITZ, ALVARO MARTINEZ,